Companies‎ > ‎US Research‎ > ‎

TESARO (Nasdaq: TSRO) | Company Profile, History, Competitors

 

TESARO (NASDAQ: TSRO) is a commercial player in the PARP space. It was founded in 2010 and headquartered in Waltham, MA.

TESARO produces PARP inhibitors for adult patients with recurring epithelial ovarian,  fallopian tube or primary peritoneal cancer who are in response to chemotherapy. In March 2017, TESARO's Zejula drug became the third approved PARPi in the United States.

Key Product Portfolio (2017)

 Brand     Status     Description
 Zejula (niraparib) CommercializingPARP inhibitor for adult patients with recurrent epithelial ovarian,  fallopian tube or primary peritoneal cancer who are in response to chemotherapy
 VARUBI (rolipitant) CommercializingCINV

Zejula (Niraparib) Drug

Zejula is one of several commercially approved PARP inhibitors. Zejula's differentiators include a broader indication, once a day dosing, and comprehensive PFS measurement. Zejula shows similar efficacy to other PARP inhibitors; however, its broader indication and once a day dosing may offer more convenience for physicians and patients.

Risks

TESARO's approved drugs may not ramp up as quickly as expected. Drugs undergoing clinical trials may not receive approval.

Management

Leon O. Moulder Jr (CEO): Leon Moulder Jr. serves as CEO since 2010. Prior, he was CEO of Abraxis Bioscence. He was also VIce Chariman of Eisari North America. Prior, he served as CEO of Mgi Pharma. Leon graduated with a Bachelors in Pharmacy at Temple University and a Master's Degree in Business Administration at University of Chicago.

Timothy Pearson (CFO): Timothy Pearson serves as CFO since 2014. Prior, he was CFO of Catalyst Health Solutions and CFO of Medimmune. He graduated with a Bachelors in Business Accounting from University of Delaware and Masters in Finance from Loyola University in New Orleans.

Grant C. Bogle (CCO): Grant Bogle serves as Chief Commercial Officer since 2015. Prior, he was VP of Pharmaceutical at McKesson Specialty Health.

Financials

 $ in millions    2013    2014 2015 2016 2017
 Revenues $0 $0 $0 $58 $223 
 Gross Profit$0 $0 $0 $57 $182 
 Operating Profit ($92)($171) ($251) ($374)  ($496)
 Net Income ($92)($171)($251) ($374) ($496)
 EPS ($2.93) ($4.79)($6.38)($7.85)($9.17)